nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—VDR—systemic lupus erythematosus	0.636	1	CbGaD
Paricalcitol—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.0177	0.146	CbGbCtD
Paricalcitol—CYP3A4—Dapsone—systemic lupus erythematosus	0.0155	0.128	CbGbCtD
Paricalcitol—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.0134	0.111	CbGbCtD
Paricalcitol—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.0134	0.111	CbGbCtD
Paricalcitol—CYP3A4—Betamethasone—systemic lupus erythematosus	0.0115	0.0949	CbGbCtD
Paricalcitol—CYP3A4—Prednisolone—systemic lupus erythematosus	0.0113	0.0937	CbGbCtD
Paricalcitol—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.0108	0.0888	CbGbCtD
Paricalcitol—CYP3A4—Prednisone—systemic lupus erythematosus	0.0107	0.0885	CbGbCtD
Paricalcitol—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.0102	0.0839	CbGbCtD
Paricalcitol—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00669	0.0552	CbGbCtD
Paricalcitol—UGT1A4—blood plasma—systemic lupus erythematosus	0.00606	0.166	CbGeAlD
Paricalcitol—UGT1A4—Arylamine metabolism—NAT2—systemic lupus erythematosus	0.00506	0.147	CbGpPWpGaD
Paricalcitol—CYP24A1—nephron tubule—systemic lupus erythematosus	0.00312	0.0855	CbGeAlD
Paricalcitol—UGT1A4—kidney—systemic lupus erythematosus	0.00275	0.0751	CbGeAlD
Paricalcitol—CYP24A1—kidney—systemic lupus erythematosus	0.00275	0.0751	CbGeAlD
Paricalcitol—CYP24A1—cortex of kidney—systemic lupus erythematosus	0.00267	0.0731	CbGeAlD
Paricalcitol—CYP24A1—Vitamin D Metabolism—RXRA—systemic lupus erythematosus	0.00236	0.0685	CbGpPWpGaD
Paricalcitol—CYP3A4—urine—systemic lupus erythematosus	0.00214	0.0584	CbGeAlD
Paricalcitol—CYP24A1—Vitamin D Metabolism—VDR—systemic lupus erythematosus	0.00214	0.062	CbGpPWpGaD
Paricalcitol—VDR—Vitamin D Metabolism—RXRA—systemic lupus erythematosus	0.00198	0.0574	CbGpPWpGaD
Paricalcitol—CYP24A1—lung—systemic lupus erythematosus	0.00195	0.0532	CbGeAlD
Paricalcitol—VDR—connective tissue—systemic lupus erythematosus	0.00178	0.0486	CbGeAlD
Paricalcitol—VDR—nephron tubule—systemic lupus erythematosus	0.00172	0.0471	CbGeAlD
Paricalcitol—Dihydrotachysterol—VDR—systemic lupus erythematosus	0.00161	0.232	CrCbGaD
Paricalcitol—VDR—skin of body—systemic lupus erythematosus	0.0016	0.0439	CbGeAlD
Paricalcitol—VDR—kidney—systemic lupus erythematosus	0.00151	0.0414	CbGeAlD
Paricalcitol—VDR—cortex of kidney—systemic lupus erythematosus	0.00147	0.0403	CbGeAlD
Paricalcitol—VDR—lymphoid tissue—systemic lupus erythematosus	0.0013	0.0355	CbGeAlD
Paricalcitol—VDR—tendon—systemic lupus erythematosus	0.00122	0.0334	CbGeAlD
Paricalcitol—VDR—bone marrow—systemic lupus erythematosus	0.00118	0.0323	CbGeAlD
Paricalcitol—CYP3A4—blood plasma—systemic lupus erythematosus	0.00112	0.0305	CbGeAlD
Paricalcitol—VDR—lung—systemic lupus erythematosus	0.00107	0.0293	CbGeAlD
Paricalcitol—Calcidiol—VDR—systemic lupus erythematosus	0.00104	0.149	CrCbGaD
Paricalcitol—Calcipotriol—VDR—systemic lupus erythematosus	0.00104	0.149	CrCbGaD
Paricalcitol—Alfacalcidol—VDR—systemic lupus erythematosus	0.00104	0.149	CrCbGaD
Paricalcitol—Calcitriol—VDR—systemic lupus erythematosus	0.000924	0.133	CrCbGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—RXRA—systemic lupus erythematosus	0.00092	0.0267	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—RXRA—systemic lupus erythematosus	0.000821	0.0238	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	0.000803	0.0233	CbGpPWpGaD
Paricalcitol—UGT1A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000744	0.0216	CbGpPWpGaD
Paricalcitol—Ergocalciferol—VDR—systemic lupus erythematosus	0.000739	0.106	CrCbGaD
Paricalcitol—VDR—Nuclear Receptors—RXRA—systemic lupus erythematosus	0.000679	0.0197	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	0.00067	0.0195	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	0.000635	0.0184	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—GADD45A—systemic lupus erythematosus	0.000621	0.018	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PRDM1—systemic lupus erythematosus	0.000606	0.0176	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—NAT2—systemic lupus erythematosus	0.000591	0.0171	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—PPARG—systemic lupus erythematosus	0.000581	0.0169	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	0.000563	0.0163	CbGpPWpGaD
Paricalcitol—Cholecalciferol—VDR—systemic lupus erythematosus	0.00056	0.0806	CrCbGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	0.00056	0.0162	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—NR3C1—systemic lupus erythematosus	0.000554	0.0161	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—RXRA—systemic lupus erythematosus	0.000537	0.0156	CbGpPWpGaD
Paricalcitol—CYP3A4—kidney—systemic lupus erythematosus	0.000505	0.0138	CbGeAlD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	0.000469	0.0136	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	0.000456	0.0132	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—NR3C1—systemic lupus erythematosus	0.000438	0.0127	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—NAT2—systemic lupus erythematosus	0.000432	0.0125	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—PPARG—systemic lupus erythematosus	0.000429	0.0125	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—NAT2—systemic lupus erythematosus	0.000426	0.0124	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—FAS—systemic lupus erythematosus	0.000405	0.0118	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—IRF5—systemic lupus erythematosus	0.000374	0.0109	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDKN1B—systemic lupus erythematosus	0.000367	0.0106	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—NAT2—systemic lupus erythematosus	0.000345	0.01	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	0.000341	0.00989	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—EP300—systemic lupus erythematosus	0.000339	0.00984	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PPARG—systemic lupus erythematosus	0.000339	0.00984	CbGpPWpGaD
Paricalcitol—CYP3A4—nervous system—systemic lupus erythematosus	0.000332	0.00907	CbGeAlD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic lupus erythematosus	0.000331	0.0096	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IL10—systemic lupus erythematosus	0.000327	0.00949	CbGpPWpGaD
Paricalcitol—CYP3A4—central nervous system—systemic lupus erythematosus	0.000319	0.00873	CbGeAlD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—systemic lupus erythematosus	0.000309	0.00896	CbGpPWpGaD
Paricalcitol—CYP3A4—Liver X Receptor Pathway—RXRA—systemic lupus erythematosus	0.000306	0.00889	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—NR3C1—systemic lupus erythematosus	0.000302	0.00878	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—GADD45A—systemic lupus erythematosus	0.00029	0.00841	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	0.000288	0.00837	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	0.000262	0.0076	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	0.000256	0.00743	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—RXRA—systemic lupus erythematosus	0.000242	0.00703	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	0.00023	0.00667	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN1A—systemic lupus erythematosus	0.000223	0.00646	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—RXRA—systemic lupus erythematosus	0.000221	0.00641	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—EP300—systemic lupus erythematosus	0.000212	0.00615	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	0.0002	0.0058	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—RXRA—systemic lupus erythematosus	0.000194	0.00562	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—FAS—systemic lupus erythematosus	0.000189	0.00549	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	0.000187	0.00542	CbGpPWpGaD
Paricalcitol—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—systemic lupus erythematosus	0.000183	0.00532	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	0.000181	0.00527	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—systemic lupus erythematosus	0.000161	0.00467	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SNRPD1—systemic lupus erythematosus	0.000153	0.00445	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—EP300—systemic lupus erythematosus	0.000153	0.00445	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MTA2—systemic lupus erythematosus	0.000139	0.00403	CbGpPWpGaD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000121	0.0035	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—JUNB—systemic lupus erythematosus	0.000106	0.00307	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	0.000104	0.00302	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CDKN1A—systemic lupus erythematosus	0.000104	0.00302	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—EP300—systemic lupus erythematosus	9.89e-05	0.00287	CbGpPWpGaD
Paricalcitol—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	9.37e-05	0.00057	CcSEcCtD
Paricalcitol—VDR—Gene Expression—TNFSF13—systemic lupus erythematosus	9.37e-05	0.00272	CbGpPWpGaD
Paricalcitol—Hypotension—Methylprednisolone—systemic lupus erythematosus	9.34e-05	0.000568	CcSEcCtD
Paricalcitol—Pain—Prednisolone—systemic lupus erythematosus	9.32e-05	0.000567	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	9.3e-05	0.0027	CbGpPWpGaD
Paricalcitol—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	9.28e-05	0.000564	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—RXRA—systemic lupus erythematosus	9.27e-05	0.00269	CbGpPWpGaD
Paricalcitol—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	9.25e-05	0.000562	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—systemic lupus erythematosus	9.25e-05	0.000562	CcSEcCtD
Paricalcitol—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	9.24e-05	0.000561	CcSEcCtD
Paricalcitol—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	9.24e-05	0.000561	CcSEcCtD
Paricalcitol—Nausea—Leflunomide—systemic lupus erythematosus	9.22e-05	0.00056	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	9.2e-05	0.000559	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	9.19e-05	0.000559	CcSEcCtD
Paricalcitol—Fatigue—Hydrocortisone—systemic lupus erythematosus	9.18e-05	0.000558	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—systemic lupus erythematosus	9.13e-05	0.000555	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	9.13e-05	0.000555	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	9.11e-05	0.000554	CcSEcCtD
Paricalcitol—Pain—Hydrocortisone—systemic lupus erythematosus	9.1e-05	0.000553	CcSEcCtD
Paricalcitol—Oedema—Dexamethasone—systemic lupus erythematosus	9.09e-05	0.000553	CcSEcCtD
Paricalcitol—Oedema—Betamethasone—systemic lupus erythematosus	9.09e-05	0.000553	CcSEcCtD
Paricalcitol—VDR—Gene Expression—SNRPB—systemic lupus erythematosus	9.07e-05	0.00263	CbGpPWpGaD
Paricalcitol—Insomnia—Triamcinolone—systemic lupus erythematosus	9.06e-05	0.000551	CcSEcCtD
Paricalcitol—Insomnia—Methylprednisolone—systemic lupus erythematosus	9.04e-05	0.00055	CcSEcCtD
Paricalcitol—Infection—Dexamethasone—systemic lupus erythematosus	9.03e-05	0.000549	CcSEcCtD
Paricalcitol—Infection—Betamethasone—systemic lupus erythematosus	9.03e-05	0.000549	CcSEcCtD
Paricalcitol—Ill-defined disorder—Prednisone—systemic lupus erythematosus	9e-05	0.000547	CcSEcCtD
Paricalcitol—Paraesthesia—Triamcinolone—systemic lupus erythematosus	9e-05	0.000547	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisolone—systemic lupus erythematosus	8.98e-05	0.000546	CcSEcCtD
Paricalcitol—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	8.98e-05	0.000546	CcSEcCtD
Paricalcitol—Anaemia—Prednisone—systemic lupus erythematosus	8.97e-05	0.000545	CcSEcCtD
Paricalcitol—Shock—Betamethasone—systemic lupus erythematosus	8.95e-05	0.000544	CcSEcCtD
Paricalcitol—Shock—Dexamethasone—systemic lupus erythematosus	8.95e-05	0.000544	CcSEcCtD
Paricalcitol—Dyspnoea—Triamcinolone—systemic lupus erythematosus	8.93e-05	0.000543	CcSEcCtD
Paricalcitol—Nervous system disorder—Betamethasone—systemic lupus erythematosus	8.92e-05	0.000542	CcSEcCtD
Paricalcitol—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	8.92e-05	0.000542	CcSEcCtD
Paricalcitol—Agitation—Prednisone—systemic lupus erythematosus	8.92e-05	0.000542	CcSEcCtD
Paricalcitol—Angioedema—Prednisone—systemic lupus erythematosus	8.87e-05	0.000539	CcSEcCtD
Paricalcitol—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	8.82e-05	0.000536	CcSEcCtD
Paricalcitol—Dyspepsia—Triamcinolone—systemic lupus erythematosus	8.82e-05	0.000536	CcSEcCtD
Paricalcitol—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	8.8e-05	0.000535	CcSEcCtD
Paricalcitol—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	8.79e-05	0.000534	CcSEcCtD
Paricalcitol—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	8.79e-05	0.000534	CcSEcCtD
Paricalcitol—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	8.77e-05	0.000533	CcSEcCtD
Paricalcitol—Malaise—Prednisone—systemic lupus erythematosus	8.75e-05	0.000532	CcSEcCtD
Paricalcitol—Vertigo—Prednisone—systemic lupus erythematosus	8.72e-05	0.00053	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—systemic lupus erythematosus	8.71e-05	0.000529	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	8.7e-05	0.000529	CcSEcCtD
Paricalcitol—Syncope—Prednisone—systemic lupus erythematosus	8.7e-05	0.000529	CcSEcCtD
Paricalcitol—Anorexia—Dexamethasone—systemic lupus erythematosus	8.67e-05	0.000527	CcSEcCtD
Paricalcitol—Anorexia—Betamethasone—systemic lupus erythematosus	8.67e-05	0.000527	CcSEcCtD
Paricalcitol—Urticaria—Prednisolone—systemic lupus erythematosus	8.66e-05	0.000526	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—systemic lupus erythematosus	8.65e-05	0.000526	CcSEcCtD
Paricalcitol—Fatigue—Triamcinolone—systemic lupus erythematosus	8.64e-05	0.000525	CcSEcCtD
Paricalcitol—Fatigue—Methylprednisolone—systemic lupus erythematosus	8.62e-05	0.000524	CcSEcCtD
Paricalcitol—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	8.61e-05	0.000523	CcSEcCtD
Paricalcitol—Asthenia—Cyclosporine—systemic lupus erythematosus	8.59e-05	0.000522	CcSEcCtD
Paricalcitol—Pain—Triamcinolone—systemic lupus erythematosus	8.57e-05	0.000521	CcSEcCtD
Paricalcitol—Loss of consciousness—Prednisone—systemic lupus erythematosus	8.53e-05	0.000518	CcSEcCtD
Paricalcitol—Hypotension—Dexamethasone—systemic lupus erythematosus	8.5e-05	0.000517	CcSEcCtD
Paricalcitol—Hypotension—Betamethasone—systemic lupus erythematosus	8.5e-05	0.000517	CcSEcCtD
Paricalcitol—Pruritus—Cyclosporine—systemic lupus erythematosus	8.47e-05	0.000515	CcSEcCtD
Paricalcitol—Urticaria—Hydrocortisone—systemic lupus erythematosus	8.46e-05	0.000514	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—systemic lupus erythematosus	8.45e-05	0.000514	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—systemic lupus erythematosus	8.41e-05	0.000512	CcSEcCtD
Paricalcitol—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	8.41e-05	0.000511	CcSEcCtD
Paricalcitol—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	8.41e-05	0.000511	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	8.4e-05	0.00051	CcSEcCtD
Paricalcitol—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	8.38e-05	0.00051	CcSEcCtD
Paricalcitol—Hypertension—Prednisone—systemic lupus erythematosus	8.38e-05	0.000509	CcSEcCtD
Paricalcitol—Chills—Methotrexate—systemic lupus erythematosus	8.36e-05	0.000508	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	8.28e-05	0.000504	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	8.28e-05	0.000504	CcSEcCtD
Paricalcitol—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	8.27e-05	0.000502	CcSEcCtD
Paricalcitol—Myalgia—Prednisone—systemic lupus erythematosus	8.26e-05	0.000502	CcSEcCtD
Paricalcitol—Arthralgia—Prednisone—systemic lupus erythematosus	8.26e-05	0.000502	CcSEcCtD
Paricalcitol—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	8.26e-05	0.000502	CcSEcCtD
Paricalcitol—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	8.24e-05	0.000501	CcSEcCtD
Paricalcitol—Anxiety—Prednisone—systemic lupus erythematosus	8.23e-05	0.0005	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—systemic lupus erythematosus	8.23e-05	0.0005	CcSEcCtD
Paricalcitol—Insomnia—Dexamethasone—systemic lupus erythematosus	8.22e-05	0.0005	CcSEcCtD
Paricalcitol—Insomnia—Betamethasone—systemic lupus erythematosus	8.22e-05	0.0005	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	8.2e-05	0.000499	CcSEcCtD
Paricalcitol—Diarrhoea—Cyclosporine—systemic lupus erythematosus	8.19e-05	0.000498	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	8.18e-05	0.000497	CcSEcCtD
Paricalcitol—Paraesthesia—Betamethasone—systemic lupus erythematosus	8.17e-05	0.000496	CcSEcCtD
Paricalcitol—Paraesthesia—Dexamethasone—systemic lupus erythematosus	8.17e-05	0.000496	CcSEcCtD
Paricalcitol—Discomfort—Prednisone—systemic lupus erythematosus	8.16e-05	0.000496	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—systemic lupus erythematosus	8.16e-05	0.000496	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—systemic lupus erythematosus	8.11e-05	0.000493	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisolone—systemic lupus erythematosus	8.03e-05	0.000488	CcSEcCtD
Paricalcitol—Dyspepsia—Betamethasone—systemic lupus erythematosus	8e-05	0.000487	CcSEcCtD
Paricalcitol—Dyspepsia—Dexamethasone—systemic lupus erythematosus	8e-05	0.000487	CcSEcCtD
Paricalcitol—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	7.99e-05	0.000486	CcSEcCtD
Paricalcitol—Urticaria—Triamcinolone—systemic lupus erythematosus	7.96e-05	0.000484	CcSEcCtD
Paricalcitol—Urticaria—Methylprednisolone—systemic lupus erythematosus	7.94e-05	0.000483	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—systemic lupus erythematosus	7.94e-05	0.000483	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—TGFB1—systemic lupus erythematosus	7.93e-05	0.0023	CbGpPWpGaD
Paricalcitol—Body temperature increased—Triamcinolone—systemic lupus erythematosus	7.92e-05	0.000482	CcSEcCtD
Paricalcitol—Dizziness—Cyclosporine—systemic lupus erythematosus	7.92e-05	0.000481	CcSEcCtD
Paricalcitol—Oedema—Prednisone—systemic lupus erythematosus	7.92e-05	0.000481	CcSEcCtD
Paricalcitol—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	7.9e-05	0.000481	CcSEcCtD
Paricalcitol—Decreased appetite—Betamethasone—systemic lupus erythematosus	7.9e-05	0.000481	CcSEcCtD
Paricalcitol—Decreased appetite—Dexamethasone—systemic lupus erythematosus	7.9e-05	0.000481	CcSEcCtD
Paricalcitol—Infection—Prednisone—systemic lupus erythematosus	7.87e-05	0.000478	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	7.85e-05	0.000477	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	7.85e-05	0.000477	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—systemic lupus erythematosus	7.84e-05	0.000477	CcSEcCtD
Paricalcitol—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	7.84e-05	0.000477	CcSEcCtD
Paricalcitol—Fatigue—Dexamethasone—systemic lupus erythematosus	7.84e-05	0.000477	CcSEcCtD
Paricalcitol—Fatigue—Betamethasone—systemic lupus erythematosus	7.84e-05	0.000477	CcSEcCtD
Paricalcitol—Shock—Prednisone—systemic lupus erythematosus	7.79e-05	0.000474	CcSEcCtD
Paricalcitol—Pain—Betamethasone—systemic lupus erythematosus	7.78e-05	0.000473	CcSEcCtD
Paricalcitol—Pain—Dexamethasone—systemic lupus erythematosus	7.78e-05	0.000473	CcSEcCtD
Paricalcitol—Nervous system disorder—Prednisone—systemic lupus erythematosus	7.77e-05	0.000472	CcSEcCtD
Paricalcitol—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	7.73e-05	0.00047	CcSEcCtD
Paricalcitol—Skin disorder—Prednisone—systemic lupus erythematosus	7.69e-05	0.000468	CcSEcCtD
Paricalcitol—Hyperhidrosis—Prednisone—systemic lupus erythematosus	7.66e-05	0.000465	CcSEcCtD
Paricalcitol—Asthenia—Hydrocortisone—systemic lupus erythematosus	7.64e-05	0.000464	CcSEcCtD
Paricalcitol—Vomiting—Cyclosporine—systemic lupus erythematosus	7.61e-05	0.000463	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—NR3C1—systemic lupus erythematosus	7.56e-05	0.00219	CbGpPWpGaD
Paricalcitol—Rash—Cyclosporine—systemic lupus erythematosus	7.55e-05	0.000459	CcSEcCtD
Paricalcitol—Anorexia—Prednisone—systemic lupus erythematosus	7.55e-05	0.000459	CcSEcCtD
Paricalcitol—Dermatitis—Cyclosporine—systemic lupus erythematosus	7.54e-05	0.000459	CcSEcCtD
Paricalcitol—Pruritus—Hydrocortisone—systemic lupus erythematosus	7.53e-05	0.000458	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	7.52e-05	0.000457	CcSEcCtD
Paricalcitol—Headache—Cyclosporine—systemic lupus erythematosus	7.5e-05	0.000456	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—systemic lupus erythematosus	7.49e-05	0.000456	CcSEcCtD
Paricalcitol—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	7.49e-05	0.000456	CcSEcCtD
Paricalcitol—Feeling abnormal—Betamethasone—systemic lupus erythematosus	7.49e-05	0.000456	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	7.44e-05	0.000452	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	7.44e-05	0.000452	CcSEcCtD
Paricalcitol—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	7.43e-05	0.000452	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—NAT2—systemic lupus erythematosus	7.39e-05	0.00215	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	7.38e-05	0.000449	CcSEcCtD
Paricalcitol—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	7.37e-05	0.000448	CcSEcCtD
Paricalcitol—Rash—Mycophenolate mofetil—systemic lupus erythematosus	7.37e-05	0.000448	CcSEcCtD
Paricalcitol—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	7.36e-05	0.000447	CcSEcCtD
Paricalcitol—Headache—Mycophenolate mofetil—systemic lupus erythematosus	7.32e-05	0.000445	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—systemic lupus erythematosus	7.31e-05	0.000445	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	7.3e-05	0.00212	CbGpPWpGaD
Paricalcitol—Vertigo—Methotrexate—systemic lupus erythematosus	7.29e-05	0.000443	CcSEcCtD
Paricalcitol—VDR—Gene Expression—HIST2H2AC—systemic lupus erythematosus	7.28e-05	0.00211	CbGpPWpGaD
Paricalcitol—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	7.28e-05	0.000443	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	7.26e-05	0.00211	CbGpPWpGaD
Paricalcitol—Leukopenia—Methotrexate—systemic lupus erythematosus	7.26e-05	0.000441	CcSEcCtD
Paricalcitol—Urticaria—Dexamethasone—systemic lupus erythematosus	7.22e-05	0.000439	CcSEcCtD
Paricalcitol—Urticaria—Betamethasone—systemic lupus erythematosus	7.22e-05	0.000439	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	7.21e-05	0.000439	CcSEcCtD
Paricalcitol—Dizziness—Prednisolone—systemic lupus erythematosus	7.21e-05	0.000438	CcSEcCtD
Paricalcitol—Asthenia—Triamcinolone—systemic lupus erythematosus	7.19e-05	0.000437	CcSEcCtD
Paricalcitol—Abdominal pain—Dexamethasone—systemic lupus erythematosus	7.19e-05	0.000437	CcSEcCtD
Paricalcitol—Body temperature increased—Dexamethasone—systemic lupus erythematosus	7.19e-05	0.000437	CcSEcCtD
Paricalcitol—Abdominal pain—Betamethasone—systemic lupus erythematosus	7.19e-05	0.000437	CcSEcCtD
Paricalcitol—Body temperature increased—Betamethasone—systemic lupus erythematosus	7.19e-05	0.000437	CcSEcCtD
Paricalcitol—Asthenia—Methylprednisolone—systemic lupus erythematosus	7.17e-05	0.000436	CcSEcCtD
Paricalcitol—Insomnia—Prednisone—systemic lupus erythematosus	7.16e-05	0.000435	CcSEcCtD
Paricalcitol—Nausea—Cyclosporine—systemic lupus erythematosus	7.11e-05	0.000432	CcSEcCtD
Paricalcitol—Paraesthesia—Prednisone—systemic lupus erythematosus	7.11e-05	0.000432	CcSEcCtD
Paricalcitol—Pruritus—Triamcinolone—systemic lupus erythematosus	7.09e-05	0.000431	CcSEcCtD
Paricalcitol—Cough—Methotrexate—systemic lupus erythematosus	7.08e-05	0.00043	CcSEcCtD
Paricalcitol—Pruritus—Methylprednisolone—systemic lupus erythematosus	7.07e-05	0.00043	CcSEcCtD
Paricalcitol—Dizziness—Hydrocortisone—systemic lupus erythematosus	7.04e-05	0.000428	CcSEcCtD
Paricalcitol—Dyspepsia—Prednisone—systemic lupus erythematosus	6.97e-05	0.000424	CcSEcCtD
Paricalcitol—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	6.94e-05	0.000422	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—systemic lupus erythematosus	6.9e-05	0.00042	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—systemic lupus erythematosus	6.9e-05	0.00042	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—systemic lupus erythematosus	6.9e-05	0.00042	CcSEcCtD
Paricalcitol—Decreased appetite—Prednisone—systemic lupus erythematosus	6.88e-05	0.000418	CcSEcCtD
Paricalcitol—Rash—Prednisolone—systemic lupus erythematosus	6.87e-05	0.000418	CcSEcCtD
Paricalcitol—Dermatitis—Prednisolone—systemic lupus erythematosus	6.86e-05	0.000417	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	6.86e-05	0.000417	CcSEcCtD
Paricalcitol—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	6.84e-05	0.000416	CcSEcCtD
Paricalcitol—Fatigue—Prednisone—systemic lupus erythematosus	6.83e-05	0.000415	CcSEcCtD
Paricalcitol—Headache—Prednisolone—systemic lupus erythematosus	6.83e-05	0.000415	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—systemic lupus erythematosus	6.82e-05	0.000415	CcSEcCtD
Paricalcitol—Constipation—Prednisone—systemic lupus erythematosus	6.77e-05	0.000412	CcSEcCtD
Paricalcitol—Vomiting—Hydrocortisone—systemic lupus erythematosus	6.77e-05	0.000411	CcSEcCtD
Paricalcitol—Rash—Hydrocortisone—systemic lupus erythematosus	6.71e-05	0.000408	CcSEcCtD
Paricalcitol—Dermatitis—Hydrocortisone—systemic lupus erythematosus	6.7e-05	0.000408	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—systemic lupus erythematosus	6.67e-05	0.000406	CcSEcCtD
Paricalcitol—Headache—Hydrocortisone—systemic lupus erythematosus	6.67e-05	0.000405	CcSEcCtD
Paricalcitol—Dizziness—Triamcinolone—systemic lupus erythematosus	6.63e-05	0.000403	CcSEcCtD
Paricalcitol—Dizziness—Methylprednisolone—systemic lupus erythematosus	6.61e-05	0.000402	CcSEcCtD
Paricalcitol—Infection—Methotrexate—systemic lupus erythematosus	6.57e-05	0.0004	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisone—systemic lupus erythematosus	6.53e-05	0.000397	CcSEcCtD
Paricalcitol—Asthenia—Dexamethasone—systemic lupus erythematosus	6.52e-05	0.000397	CcSEcCtD
Paricalcitol—Asthenia—Betamethasone—systemic lupus erythematosus	6.52e-05	0.000397	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—systemic lupus erythematosus	6.49e-05	0.000395	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	6.48e-05	0.000394	CcSEcCtD
Paricalcitol—Nausea—Prednisolone—systemic lupus erythematosus	6.47e-05	0.000394	CcSEcCtD
Paricalcitol—Pruritus—Dexamethasone—systemic lupus erythematosus	6.43e-05	0.000391	CcSEcCtD
Paricalcitol—Pruritus—Betamethasone—systemic lupus erythematosus	6.43e-05	0.000391	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—systemic lupus erythematosus	6.43e-05	0.000391	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	6.4e-05	0.000389	CcSEcCtD
Paricalcitol—Vomiting—Triamcinolone—systemic lupus erythematosus	6.37e-05	0.000387	CcSEcCtD
Paricalcitol—Vomiting—Methylprednisolone—systemic lupus erythematosus	6.36e-05	0.000387	CcSEcCtD
Paricalcitol—Nausea—Hydrocortisone—systemic lupus erythematosus	6.32e-05	0.000384	CcSEcCtD
Paricalcitol—Rash—Triamcinolone—systemic lupus erythematosus	6.32e-05	0.000384	CcSEcCtD
Paricalcitol—Dermatitis—Triamcinolone—systemic lupus erythematosus	6.31e-05	0.000384	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—systemic lupus erythematosus	6.31e-05	0.000384	CcSEcCtD
Paricalcitol—Rash—Methylprednisolone—systemic lupus erythematosus	6.3e-05	0.000383	CcSEcCtD
Paricalcitol—Dermatitis—Methylprednisolone—systemic lupus erythematosus	6.3e-05	0.000383	CcSEcCtD
Paricalcitol—Urticaria—Prednisone—systemic lupus erythematosus	6.29e-05	0.000382	CcSEcCtD
Paricalcitol—Headache—Triamcinolone—systemic lupus erythematosus	6.28e-05	0.000382	CcSEcCtD
Paricalcitol—Headache—Methylprednisolone—systemic lupus erythematosus	6.26e-05	0.000381	CcSEcCtD
Paricalcitol—Body temperature increased—Prednisone—systemic lupus erythematosus	6.26e-05	0.000381	CcSEcCtD
Paricalcitol—Abdominal pain—Prednisone—systemic lupus erythematosus	6.26e-05	0.000381	CcSEcCtD
Paricalcitol—Diarrhoea—Betamethasone—systemic lupus erythematosus	6.22e-05	0.000378	CcSEcCtD
Paricalcitol—Diarrhoea—Dexamethasone—systemic lupus erythematosus	6.22e-05	0.000378	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—systemic lupus erythematosus	6.18e-05	0.000376	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	6.03e-05	0.000367	CcSEcCtD
Paricalcitol—Dizziness—Betamethasone—systemic lupus erythematosus	6.01e-05	0.000366	CcSEcCtD
Paricalcitol—Dizziness—Dexamethasone—systemic lupus erythematosus	6.01e-05	0.000366	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—systemic lupus erythematosus	5.99e-05	0.000364	CcSEcCtD
Paricalcitol—Nausea—Triamcinolone—systemic lupus erythematosus	5.95e-05	0.000362	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—systemic lupus erythematosus	5.94e-05	0.000361	CcSEcCtD
Paricalcitol—Nausea—Methylprednisolone—systemic lupus erythematosus	5.94e-05	0.000361	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	5.92e-05	0.00172	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NAT2—systemic lupus erythematosus	5.91e-05	0.00172	CbGpPWpGaD
Paricalcitol—Dyspnoea—Methotrexate—systemic lupus erythematosus	5.9e-05	0.000359	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—systemic lupus erythematosus	5.88e-05	0.000358	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.87e-05	0.00171	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—PPARG—systemic lupus erythematosus	5.86e-05	0.0017	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Prednisone—systemic lupus erythematosus	5.83e-05	0.000355	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—systemic lupus erythematosus	5.83e-05	0.000354	CcSEcCtD
Paricalcitol—Vomiting—Dexamethasone—systemic lupus erythematosus	5.78e-05	0.000351	CcSEcCtD
Paricalcitol—Vomiting—Betamethasone—systemic lupus erythematosus	5.78e-05	0.000351	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—systemic lupus erythematosus	5.75e-05	0.00035	CcSEcCtD
Paricalcitol—Rash—Betamethasone—systemic lupus erythematosus	5.73e-05	0.000349	CcSEcCtD
Paricalcitol—Rash—Dexamethasone—systemic lupus erythematosus	5.73e-05	0.000349	CcSEcCtD
Paricalcitol—Dermatitis—Dexamethasone—systemic lupus erythematosus	5.73e-05	0.000348	CcSEcCtD
Paricalcitol—Dermatitis—Betamethasone—systemic lupus erythematosus	5.73e-05	0.000348	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	5.71e-05	0.000347	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—systemic lupus erythematosus	5.71e-05	0.000347	CcSEcCtD
Paricalcitol—Headache—Betamethasone—systemic lupus erythematosus	5.7e-05	0.000346	CcSEcCtD
Paricalcitol—Headache—Dexamethasone—systemic lupus erythematosus	5.7e-05	0.000346	CcSEcCtD
Paricalcitol—Asthenia—Prednisone—systemic lupus erythematosus	5.68e-05	0.000345	CcSEcCtD
Paricalcitol—Pain—Methotrexate—systemic lupus erythematosus	5.66e-05	0.000344	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	5.61e-05	0.00163	CbGpPWpGaD
Paricalcitol—Pruritus—Prednisone—systemic lupus erythematosus	5.6e-05	0.000341	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	5.53e-05	0.00161	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Methotrexate—systemic lupus erythematosus	5.45e-05	0.000332	CcSEcCtD
Paricalcitol—Diarrhoea—Prednisone—systemic lupus erythematosus	5.42e-05	0.000329	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	5.41e-05	0.000329	CcSEcCtD
Paricalcitol—Nausea—Betamethasone—systemic lupus erythematosus	5.4e-05	0.000328	CcSEcCtD
Paricalcitol—Nausea—Dexamethasone—systemic lupus erythematosus	5.4e-05	0.000328	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	5.28e-05	0.00153	CbGpPWpGaD
Paricalcitol—Urticaria—Methotrexate—systemic lupus erythematosus	5.26e-05	0.00032	CcSEcCtD
Paricalcitol—Dizziness—Prednisone—systemic lupus erythematosus	5.24e-05	0.000318	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—systemic lupus erythematosus	5.23e-05	0.000318	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—systemic lupus erythematosus	5.23e-05	0.000318	CcSEcCtD
Paricalcitol—VDR—Gene Expression—JUNB—systemic lupus erythematosus	5.09e-05	0.00148	CbGpPWpGaD
Paricalcitol—Vomiting—Prednisone—systemic lupus erythematosus	5.03e-05	0.000306	CcSEcCtD
Paricalcitol—Rash—Prednisone—systemic lupus erythematosus	4.99e-05	0.000304	CcSEcCtD
Paricalcitol—Dermatitis—Prednisone—systemic lupus erythematosus	4.99e-05	0.000303	CcSEcCtD
Paricalcitol—Headache—Prednisone—systemic lupus erythematosus	4.96e-05	0.000302	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—systemic lupus erythematosus	4.88e-05	0.000296	CcSEcCtD
Paricalcitol—Asthenia—Methotrexate—systemic lupus erythematosus	4.75e-05	0.000289	CcSEcCtD
Paricalcitol—Nausea—Prednisone—systemic lupus erythematosus	4.7e-05	0.000286	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—systemic lupus erythematosus	4.68e-05	0.000285	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.62e-05	0.00134	CbGpPWpGaD
Paricalcitol—Diarrhoea—Methotrexate—systemic lupus erythematosus	4.53e-05	0.000275	CcSEcCtD
Paricalcitol—VDR—Gene Expression—RXRA—systemic lupus erythematosus	4.46e-05	0.0013	CbGpPWpGaD
Paricalcitol—Dizziness—Methotrexate—systemic lupus erythematosus	4.38e-05	0.000266	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—systemic lupus erythematosus	4.21e-05	0.000256	CcSEcCtD
Paricalcitol—Rash—Methotrexate—systemic lupus erythematosus	4.17e-05	0.000254	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—systemic lupus erythematosus	4.17e-05	0.000253	CcSEcCtD
Paricalcitol—Headache—Methotrexate—systemic lupus erythematosus	4.15e-05	0.000252	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—RXRA—systemic lupus erythematosus	4.14e-05	0.0012	CbGpPWpGaD
Paricalcitol—Nausea—Methotrexate—systemic lupus erythematosus	3.93e-05	0.000239	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.84e-05	0.00112	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NR3C1—systemic lupus erythematosus	3.64e-05	0.00106	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—RXRA—systemic lupus erythematosus	3.31e-05	0.000962	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	3.14e-05	0.000913	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PPARG—systemic lupus erythematosus	2.82e-05	0.000818	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPARG—systemic lupus erythematosus	2.62e-05	0.000759	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALB—systemic lupus erythematosus	2.35e-05	0.000683	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NOS3—systemic lupus erythematosus	2.25e-05	0.000653	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPARG—systemic lupus erythematosus	2.09e-05	0.000607	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—systemic lupus erythematosus	2.06e-05	0.000597	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALB—systemic lupus erythematosus	1.88e-05	0.000546	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NOS3—systemic lupus erythematosus	1.8e-05	0.000522	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—EP300—systemic lupus erythematosus	1.71e-05	0.000497	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—systemic lupus erythematosus	1.65e-05	0.000478	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—EP300—systemic lupus erythematosus	1.37e-05	0.000397	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	9.59e-06	0.000278	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	5.38e-06	0.000156	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	3.39e-06	9.86e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	3.05e-06	8.86e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	2.92e-06	8.48e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	2.67e-06	7.75e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	2.22e-06	6.45e-05	CbGpPWpGaD
